Secondary offering priced well below previous close
Nuvectis Pharma (NASDAQ:NVCT) shares dropped 25% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company priced a $100 million public offering at $20.00 per share, substantially below Monday’s closing price of $28.53.
The company is issuing 5,000,000 shares of common stock, with the offering price representing a discount of roughly 30% to the previous session’s close, prompting a sharp sell-off in the shares.
Underwriters receive additional share option
Nuvectis has also granted the underwriting syndicate a 30-day option to purchase up to 750,000 additional common shares at the public offering price, less underwriting discounts and commissions.
The transaction is expected to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions.
Cantor is serving as the sole book-running manager for the offering. H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners and Titan Partners, a division of American Capital Partners, are acting as co-managers.